Search Results

You are looking at 1 - 10 of 374 items :

  • "Myelodysplastic syndromes" x
Clear All

Nebe C.T. Introduction Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are malignant diseases of the hematopoietic stem cell, characterized by differentiation and maturation disorders of hematopoiesis, cytopenia and clonal expansion of varying degrees. Various pathophysiological phenomena are observed in this context, such as chromosomal, molecular and epigenetic changes in the hematopoietic stem cell, as well as alterations to the bone marrow stroma. Both groups of diseases are closely related pathophysiologically, and transitions from MDS to

decreases in situations of central thrombocytopenia [ 2 ]. However, patients with myelodysplastic syndromes (MDS) with increased IPF have been described, even in the absence of thrombocytopenia; in such cases, IPF would not be associated with an increase in megakaryopoiesis. In addition, there is literature that demonstrates a relationship between the increase in IPF and the poor prognosis in patients with MDS [ 3 ], [ 4 ]. The aim of our study was to evaluate the IPF in patients diagnosed with MDS in our center, alongside with classic parameters of poor prognosis

References 1. Elghetany TM, Bhatla T. Myelodysplastic Syndromes and Myeloproliferative Disorders. Lanzkowsky P. Hofmann I. Jeffrey M. Lipton Lanzkowsky’s Manual of Pediatric Hematology and Oncology. Sixth Edition Elsevier. 2016, London, 348-351. 2. Hasle H, Niemeyer CM, Chessells JM. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17(2):277-282. DOI: 10.1038/sj.leu.2402765 3. Disperati P, Ichim CV, Tkachuk D. Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease

Clin Chem Lab Med 2008;46(1):85–88 2008 by Walter de Gruyter • Berlin • New York. DOI 10.1515/CCLM.2008.012 2007/264 Article in press - uncorrected proof A new high-throughput screening method for the detection of chronic lymphatic leukemia and myelodysplastic syndrome Elisabeth Haschke-Becher1,*, Michael Vockenhuber1, Paul Niedetzky1, Uwe Totzke2 and Christian Gabriel3 1 Institute of Laboratory Medicine, Elisabethinen Hospital Linz, Linz, Austria 2 Healthcare Project Management (HPM), Geneva, Switzerland 3 Red Cross Transfusion Service of Upper Austria, Linz

Introduction Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid neoplasms characterized by cytopenias and dysplastic hematopoiesis. About 30% of cases of MDS eventually transform into acute myeloid leukemia (AML) [ 1 ], [ 2 ], [ 3 ]. The pathogenesis of MDS remains poorly defined. Genetic alterations and epigenetic modifications are well known to play vital roles in the occurrence and development of MDS. Cytogenetic abnormalities are detectable in about 40% of patients with de novo MDS [ 4 ], [ 5 ]. A fair number of DNA methylation and gene

Introduction Myelodysplastic syndrome (MDS), characterized by dysplastic differentiation and ineffective hematopoiesis, can result in variable degrees of peripheral blood (PB) cytopenias and have high risk of progression to acute myeloid leukemia (AML) [ 1 ]. The pathogenesis of MDS involves highly complex and diverse disrupted critical biologic pathways [ 1 ], [ 2 ]. Genetic changes and epigenetic alterations are well known to play crucial roles in the initiation and progression of MDS [ 2 ]. Clinical outcome of patients with MDS is highly variable with the

[1] Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51(2):189–199 [2] Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, vol 2. 4th edn. IARC Press, Lyon [3] Sanchez JF (2011) Treatment of myelodysplastic syndromes in elderly patients. Adv Ther 28Suppl 2:1–9 [4] Blum W (2010) How much? How frequent? How long? A clinical guide to new

, Lecumberri R, Calasanz MJ, Odero MD, Bendandi M, et al. Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: clinical and genetic features of two cases. Cancer Genetics and Cytogenetics 2003 Jul; 143(2):178-81. DOI: 10.1016/S0165-4608(02)00859-2 24. Lobe I, Rigal-Huguet F, Vekhoff A, Desablens B, Bordessoule D, Mounier C, et al. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia. 2003 Aug;17(8):1600-4. DOI: 10.1038/sj.leu.2403034 25. Coliţă A, Nicoară S, Butoianu E, Munteanu N, Ursea C, Poppa C

Introduction Myelodysplastic syndrome (MDS) is a heterogeneous clonal hemopoietic stem cell disease characterized by various levels of cytopenias and abnormal myeloid cell differentiation and maturation in addition to acute leukemia transformation risk. Although cytopenia (anemia, neutropenia, and thrombocytopenia) is seen in MDS patients, the bone marrow (BM) is often hypercellular and dysplastic, and the functions of the blood cells in circulation are disrupted. Although MDS could develop de novo, it could also develop secondary to previously administered

References 1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol, 1982, 51:189-199. 2. Cazzola M, Malcovati L: Myelodysplastic syndromes -coping with ineffective hematopoiesis. N Engl J Med, 2005, 352: 536-538. 3. Vardiman JW, Harris NL, Brunning RD: The new World Health Organization classification of myeloid neoplasms: Blood, 2002, 100:2292-2302. 4. Fenaux P: Myelodysplastic syndromes: from pathogenesis and prognosis to treatment. SeminHematol., 2004